Former Ovid CEO Dr. Jeremy Levin’s Rallying Cry for Biotech

Why It Matters

Elevating biotech to a strategic status could unlock long‑term capital, safeguard U.S. leadership in drug innovation, and blunt regulatory pressures that threaten the sector’s growth.

Key Takeaways

• Levin's book urges biotech to be recognized as a strategic U.S. industry.
• He calls for tax incentives similar to housing and defense sectors.
• Advocates rebuilding patient trust to reduce punitive legislation.
• Warns that without long‑term capital, innovation may shift to China.

Pulse Analysis

Jeremy Levin, a veteran of Bristol‑Myers Squibb, Teva and Ovid Therapeutics, has turned his attention to the macro‑policy environment that underpins American biotech. In *Biotech in the Balance*, released May 19, he argues that the sector faces an unprecedented convergence of regulatory uncertainty, NIH budget cuts, and a broader erosion of public trust that mirrors challenges in traditional pharma. Levin points to recent FDA disruptions and immigration hurdles as early warning signs that could choke the pipeline of high‑risk, high‑reward research if not addressed promptly.

The core of Levin’s prescription is to rebrand biotech as a strategic national asset, on par with housing, defense, or agriculture. He proposes targeted tax credits for early‑stage R&D, a streamlined FDA pathway for innovative therapies, and a concerted effort to “re‑bond” with patients through transparent clinical‑trial communication. By separating the industry’s image from the pricing controversies of big‑pharma, Levin believes legislators will be more inclined to enact supportive legislation, while CEOs can rally their teams around a clear, purpose‑driven narrative.

If the United States fails to adopt these measures, Levin warns that capital will follow the incentives, accelerating a migration of breakthrough drug development to China, which already enjoys a coordinated state‑backed biotech strategy. For investors, the message is a call to shift from short‑term, late‑stage bets to long‑term funding of pioneering platforms. A strategic policy overhaul could preserve America’s competitive edge, sustain a robust pipeline of novel therapies, and ultimately protect patient outcomes while delivering sustained economic returns.